MX2020001274A - Fotoregulina3, moduladora de los genes de los fotorreceptores para el tratamiento de enfermedades de la retina. - Google Patents

Fotoregulina3, moduladora de los genes de los fotorreceptores para el tratamiento de enfermedades de la retina.

Info

Publication number
MX2020001274A
MX2020001274A MX2020001274A MX2020001274A MX2020001274A MX 2020001274 A MX2020001274 A MX 2020001274A MX 2020001274 A MX2020001274 A MX 2020001274A MX 2020001274 A MX2020001274 A MX 2020001274A MX 2020001274 A MX2020001274 A MX 2020001274A
Authority
MX
Mexico
Prior art keywords
photoregulin
treatment
retinal disease
gene modulator
methods
Prior art date
Application number
MX2020001274A
Other languages
English (en)
Spanish (es)
Inventor
Thomas A Reh
Paul Nakamura
Andy Shimchuk
Shibing Tang
Sheng Ding
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of MX2020001274A publication Critical patent/MX2020001274A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MX2020001274A 2017-08-10 2018-08-10 Fotoregulina3, moduladora de los genes de los fotorreceptores para el tratamiento de enfermedades de la retina. MX2020001274A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762543782P 2017-08-10 2017-08-10
PCT/US2018/046272 WO2019032999A1 (en) 2017-08-10 2018-08-10 PHOTORECEPTOR GENE MODULATOR PHOTOREGULIN 3 FOR THE TREATMENT OF RETINAL DISEASE

Publications (1)

Publication Number Publication Date
MX2020001274A true MX2020001274A (es) 2020-09-22

Family

ID=65272549

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001274A MX2020001274A (es) 2017-08-10 2018-08-10 Fotoregulina3, moduladora de los genes de los fotorreceptores para el tratamiento de enfermedades de la retina.

Country Status (8)

Country Link
US (1) US20200368234A1 (enExample)
EP (1) EP3664801A4 (enExample)
JP (1) JP2020530459A (enExample)
CN (1) CN111093657A (enExample)
AU (1) AU2018313990A1 (enExample)
CA (1) CA3072175A1 (enExample)
MX (1) MX2020001274A (enExample)
WO (1) WO2019032999A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2906815A1 (en) 2013-03-15 2014-09-18 Ocata Therapeutics, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014134627A1 (en) * 2013-03-01 2014-09-04 The Schepens Eye Research Institute, Inc. Methods for modulating development and function of photoreceptors cells
WO2016160718A1 (en) * 2015-03-27 2016-10-06 University Of Washington Methods for treatment of retinal disease by photoreceptor gene expression modulation
CN105343107A (zh) * 2015-12-03 2016-02-24 上海中医药大学附属岳阳中西医结合医院 雷公藤红素在制备防治视网膜退行性改变相关疾病药物中的应用

Also Published As

Publication number Publication date
EP3664801A1 (en) 2020-06-17
EP3664801A4 (en) 2021-06-23
CN111093657A (zh) 2020-05-01
AU2018313990A1 (en) 2020-02-27
CA3072175A1 (en) 2019-02-14
US20200368234A1 (en) 2020-11-26
JP2020530459A (ja) 2020-10-22
WO2019032999A1 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
WO2017201527A3 (en) Gene therapy methods for age-related diseases and conditions
MX2018005286A (es) Constructo genetico.
HK1246419A1 (zh) 用於自适应医疗决策支持的系统和方法
MX2023004922A (es) Inhibidores del factor de crecimiento endotelial vascular (vegf) para usarse en el tratamiento de degeneracion macular humeda.
ZA202103256B (en) Animal models, screening methods, and treatment methods for intraocular diseases or disorders
WO2015143418A3 (en) Gene therapy for retinitis pigmentosa
WO2016037157A3 (en) Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
EP4484443A3 (en) Materials and methods for treatment of friedreich ataxia and other related disorders
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
WO2019173795A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
MX2018015289A (es) Dispositivos de traccion peniana.
MX2020007586A (es) Proceso de fabricacion de moduladores de somatostatina.
SG10201902285SA (en) Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
IL287758A (en) Anti-sema3a antibodies and their use for the treatment of eyes or eye diseases
EP4389894A3 (en) Riboswitch modulated gene therapy for retinal diseases
PH12017500998A1 (en) Treatment of ocular conditions using progenitor cells
WO2015185945A3 (en) Polypeptides and uses thereof
MX2020005603A (es) Imitadores mir29 para el tratamiento de la fibrosis ocular.
WO2019079698A8 (en) Tissue products with variations in mechanical properties and methods of treatment
MX2021011151A (es) Fitoecdisonas y los derivados de las mismas para su uso en el tratamiento de enfermedades neuromusculares.
WO2016182812A8 (en) Activation of neuronal store-operated calcium entry pathway for the treatment of alzheimer's disease
EP4272830A3 (en) Tissue organoids
IL291522A (en) Anti-nrp1a antibodies and their uses for the treatment of eyes or eye diseases
MX2019007012A (es) Marcadores geneticos humanos asociados con la respuesta a tratamientos que se dirigen a la toxina b de clostridium difficile.
MX2017011994A (es) Metodo para mejorar la funcion vesical.